Seagen, Genmab See Broad Cervical Cancer Opportunity For Tisotumab Vedotin
US FDA Clears Monotherapy Use
At ESMO, data showed objective response benefit in combination with carboplatin in first-line therapy, and with Keytruda in second- or third-line treatment. The antibody-drug conjugate obtained US approval on 20 September as monotherapy.
You may also be interested in...
In addition to securing a key position in first-line disease, Keytruda has potential to expand its presence in later lines with combination data from Seagen/Genmab’s Tivdak.
US FDA-approved belantamab mafodotin is indicated for heavily pre-treated multiple myeloma and has a list price of $23,900 per month. Its REMS could limit initial uptake, but response rates have been encouraging.
Benefits of the BCMA-directed antibody-drug conjugate outweigh its ocular risks in heavily pretreated multiple myeloma patients, Oncologic Drugs Advisory Committee says at the conclusion of a virtual meeting beset by technical problems.